Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

Abstract Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of chemotherapy. We evaluated the effectiveness of fulvestrant as first-line in patients with estrogen receptor (ER)-positive ABC with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	I. Blancas, C. Olier, V. Conde, J. L. Bayo, C. Herrero, I. Zarcos-Pedrinaci, F. Carabantes, J. M. Baena-Cañada, J. Cruz, M. Ruiz-Borrego
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ed9027d233a645fe8b379093aa99b6f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ed9027d233a645fe8b379093aa99b6f0
record_format	dspace
spelling	oai:doaj.org-article:ed9027d233a645fe8b379093aa99b6f02021-12-02T10:54:15ZReal-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer10.1038/s41598-021-83622-12045-2322https://doaj.org/article/ed9027d233a645fe8b379093aa99b6f02021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83622-1https://doaj.org/toc/2045-2322Abstract Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of chemotherapy. We evaluated the effectiveness of fulvestrant as first-line in patients with estrogen receptor (ER)-positive ABC with relapse during or after adjuvant anti-estrogenic therapy in real-world settings. Retrospective, observational study involving 171 postmenopausal women with ER-positive ABC who received fulvestrant as first-line between January 2011 and May 2018 in Spanish hospitals. With a median follow-up of 31.4 months, the progression-free survival (PFS) with fulvestrant was 14.6 months. No differences were seen in the visceral metastatic (14.3 months) versus non-visceral (14.6 months) metastatic subgroup for PFS. Overall response rate and clinical benefit rate were 35.2% and 82.8%. Overall survival was 43.1 months. The duration of the clinical benefit was 19.2 months. Patients with ECOG performance status 0 at the start of treatment showed a significant greater clinical benefit rate and overall survival than with ECOG 1–2. Results in real-world settings are in concordance with randomized clinical trials. Fulvestrant continues to demonstrate clinical benefits in real-world settings and appears be well tolerated as first-line for the treatment of postmenopausal women with ER-positive ABC.I. BlancasC. OlierV. CondeJ. L. BayoC. HerreroI. Zarcos-PedrinaciF. CarabantesJ. M. Baena-CañadaJ. CruzM. Ruiz-BorregoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q I. Blancas C. Olier V. Conde J. L. Bayo C. Herrero I. Zarcos-Pedrinaci F. Carabantes J. M. Baena-Cañada J. Cruz M. Ruiz-Borrego Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
description	Abstract Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of chemotherapy. We evaluated the effectiveness of fulvestrant as first-line in patients with estrogen receptor (ER)-positive ABC with relapse during or after adjuvant anti-estrogenic therapy in real-world settings. Retrospective, observational study involving 171 postmenopausal women with ER-positive ABC who received fulvestrant as first-line between January 2011 and May 2018 in Spanish hospitals. With a median follow-up of 31.4 months, the progression-free survival (PFS) with fulvestrant was 14.6 months. No differences were seen in the visceral metastatic (14.3 months) versus non-visceral (14.6 months) metastatic subgroup for PFS. Overall response rate and clinical benefit rate were 35.2% and 82.8%. Overall survival was 43.1 months. The duration of the clinical benefit was 19.2 months. Patients with ECOG performance status 0 at the start of treatment showed a significant greater clinical benefit rate and overall survival than with ECOG 1–2. Results in real-world settings are in concordance with randomized clinical trials. Fulvestrant continues to demonstrate clinical benefits in real-world settings and appears be well tolerated as first-line for the treatment of postmenopausal women with ER-positive ABC.
format	article
author	I. Blancas C. Olier V. Conde J. L. Bayo C. Herrero I. Zarcos-Pedrinaci F. Carabantes J. M. Baena-Cañada J. Cruz M. Ruiz-Borrego
author_facet	I. Blancas C. Olier V. Conde J. L. Bayo C. Herrero I. Zarcos-Pedrinaci F. Carabantes J. M. Baena-Cañada J. Cruz M. Ruiz-Borrego
author_sort	I. Blancas
title	Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
title_short	Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
title_full	Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
title_fullStr	Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
title_full_unstemmed	Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
title_sort	real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ed9027d233a645fe8b379093aa99b6f0
work_keys_str_mv	AT iblancas realworlddataoffulvestrantasfirstlinetreatmentofpostmenopausalwomenwithestrogenreceptorpositivemetastaticbreastcancer AT colier realworlddataoffulvestrantasfirstlinetreatmentofpostmenopausalwomenwithestrogenreceptorpositivemetastaticbreastcancer AT vconde realworlddataoffulvestrantasfirstlinetreatmentofpostmenopausalwomenwithestrogenreceptorpositivemetastaticbreastcancer AT jlbayo realworlddataoffulvestrantasfirstlinetreatmentofpostmenopausalwomenwithestrogenreceptorpositivemetastaticbreastcancer AT cherrero realworlddataoffulvestrantasfirstlinetreatmentofpostmenopausalwomenwithestrogenreceptorpositivemetastaticbreastcancer AT izarcospedrinaci realworlddataoffulvestrantasfirstlinetreatmentofpostmenopausalwomenwithestrogenreceptorpositivemetastaticbreastcancer AT fcarabantes realworlddataoffulvestrantasfirstlinetreatmentofpostmenopausalwomenwithestrogenreceptorpositivemetastaticbreastcancer AT jmbaenacanada realworlddataoffulvestrantasfirstlinetreatmentofpostmenopausalwomenwithestrogenreceptorpositivemetastaticbreastcancer AT jcruz realworlddataoffulvestrantasfirstlinetreatmentofpostmenopausalwomenwithestrogenreceptorpositivemetastaticbreastcancer AT mruizborrego realworlddataoffulvestrantasfirstlinetreatmentofpostmenopausalwomenwithestrogenreceptorpositivemetastaticbreastcancer
_version_	1718396504268341248

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

Ejemplares similares